Hong Kong and Korean biotech leaders through Stock Connect.
Confirmed 30% bonus issue: 0.3 new shares per existing common or other share. August 6, 2026 is the shareholder record date; the new shares are scheduled to be listed and begin trading on August 26, 2026.
Yuhan Corp is scheduled to release its Q2 2026 earnings results on August 18, 2026. Analysts forecast the results will meet market expectations, supported by a one-time milestone payment of KRW 44.9 billion for the European commercialization of Lazertinib, with estimated revenue of KRW 634.4 billion and operating profit of KRW 66.5 billion forecasted. This event is scheduled.
Importance is estimated as 'Medium' as earnings announcements can often lead to significant price movements; Q2 2026 earnings release scheduled.
Q2 2026 earnings release scheduled for 2026-07-23. Analysts forecast revenue of approximately 1.32 trillion KRW and operating profit of 600 billion KRW forecasted.
The company announced it received a response letter from the U.S. FDA for its Pre-ANDA (Abbreviated New Drug Application) for its oral semaglutide generic, confirming the development pathway. The stock price increased by the daily limit (+29.82%) on July 20, 2026.
The company announced the temporary postponement of its planned uplisting from the KOSDAQ to the KOSPI market, citing analysis of potential passive fund outflows.
Partner company Johnson & Johnson announced on July 15, 2026, that global sales of the Rybrevant and Lazcluze (Lazertinib) combination therapy grew 60.8% year-over-year to $289 million in Q2 2026, indicating strong market uptake and a positive outlook for Yuhan's royalty income.
Analysts forecast a significant increase in Q2 2026 operating profit (over 100% YoY) due to the Eli Lilly deal, estimated to result in a 5-10% price impact due to earnings growth forecasted.
The company is expected to announce the Korean Ministry of Food and Drug Safety (MFDS) approval for a Phase 1 clinical trial of CT-P68 on July 15, 2026; low importance is estimated as early-stage clinical trials typically have limited immediate price impact, expected.
CEO Choi Ho-il announced the acquisition of 10,000 company shares on 2026-07-14 to bolster management responsibility and shareholder confidence following recent stock price declines.
OliX to present positive non-human primate data for obesity treatment OLX501A and announce clinical trial plans at its R&D Day on July 14, 2026; significant fat reduction results suggest a Medium price impact scheduled
Announced the expansion of a research service contract with Pfizer for an oral peptide obesity treatment on 2026-07-14. The contract value increased by 37.8% to ₩2.53 billion and the term was extended to Feb 2028.